Abstract
Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Drug Design, Development and Therapy |
Vol/bind | 4 |
Sider (fra-til) | 107-16 |
Antal sider | 10 |
ISSN | 1177-8881 |
Status | Udgivet - 1 jan. 2010 |